Do you want to read an article? Please log in or register.
The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating and gastric emptying in subjects with obesity
Obesity and Bariatric Surgery
Related content
Obesity and Bariatric Surgery
Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study
Diabetologia.
Bergmann NC, Lund A, Gasbjerg LS, Meessen ECE, Andersen MM, Bergmann S, Hartmann B, Holst JJ, Jessen L, Christensen MB, Vilsbøll T, Knop FK
doi: 10.1007/s00125-018-
COMMENTED
Diabetes - GeneralType 2 DiabetesGlycemic Control
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
Diabetes Care.
Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, Holst AG, Annett MP, Aroda VR
doi: 10.2337/dc17-0417.
Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial
Lancet Gastroenterol Hepatol.
Halawi H, Khemani D, Eckert D, O'Neill J, Kadouh H, Grothe K, Clark MM, Burton DD, Vella A, Acosta A, Zinsmeister AR, Camilleri M
doi: 10.1016/
Diabetes - GeneralType 2 DiabetesGlycemic Control
Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial
JAMA.
Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J
doi: 10.1001/jama.2017.14752.
Type 2 Diabetes
Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial
Diabetologia.
McCrimmon RJ, Catarig AM, Frias JP, Lausvig NL, le Roux CW, Thielke D, Lingvay I
doi: 10.1007/s00125-019-05065-8.
Diabetes - GeneralType 2 DiabetesGlycemic Control
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
Lancet Diabetes Endocrinol.
Aroda VR, Bain SC, Cariou B, Piletič M, Rose L, Axelsen M, Rowe E, DeVries JH
doi: 10.1016/S2213-8587(17)
COMMENTED
Obesity and Bariatric Surgery
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
JAMA
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D, STEP 4 Investigators.
doi: 10.1001/jama.2021.3224
Diabetes - General
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Lancet.
O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, Carson CG, Jepsen CH, Kabisch M, Wilding JPH
doi: 10.1016/S0140-6736
Type 2 DiabetesGlycemic Control
Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study
Front Endocrinol (Lausanne)
Sanada J, Kimura T, Shimoda M, Tomita A, Fushimi Y, Kinoshita T, Obata A, Okauchi S, Hirukawa H, Kohara K, Tatsumi F, Nakanishi S, Mune T, Kaku K, Kaneto H
doi: 10.3389/fendo.2021.714447